Aduro is the Latest – and Hottest – Oncology IPO
Insights - Aduro Biotech (ADRO) begins trading on Wednesday morning at 10:25 ET having completed a $119 million IPO that values the immunotherapy company at just over … Continue Reading
Read NowInsights
Arrowhead Cleared for New Study in Hepatitis B
Insights - A week after the FDA modified a similar restriction on Tekmira Pharmaceuticals (TKMR), the federal agency has cleared Arrowhead Research (ARWR) to proceed with a multiple-dose Phase 2b clinical study … Continue Reading
Read Now
Our Top Stories from this Week in Healthcare
Insights - The talk of a bubble in biotech seems to have subsided (temporarily, no doubt), and the sector-tracking iShares Nasdaq Biotech ETF (IBB) has continued higher … Continue Reading
Read Now
AstraZeneca Picks First Candidate from Regulus’ Discovery Collab
Insights - Almost three years after an initial collaboration was announced, AstraZeneca (AZN) has selected the first clinical candidate from a discovery program with Regulus Therapeutics (RGLS). RGLS jumped … Continue Reading
Read Now
Dyax Adds Over $1 Billion in Market Value on Early Drug Results
Insights - Dyax Corp. (DYAX) saw a gain of over 40% in pre-market trading Wednesday with the release of phase 1b results for DX-2930, an inhibitor of … Continue Reading
Read Now
Your Guide to M&A Monday
Insights - Monday morning was jam-packed with deal flow in biotech. Here's a 60-second primer.
Read Now
OHRP Drops on Latest Clinical Trial Results
Insights - Top-line results from Ohr Pharmaceuticals’ (OHRP) phase II IMPACT study, testing its squalamine eyedrops in age-related macular degeneration (wet-AMD), had a crushing effect on the stock Friday. … Continue Reading
Read Now